Article ; Online: Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
2020 Volume 51, Issue 6, Page(s) 577–581
Abstract: ... susceptible to sofosbuvir and we were convinced to design and run a clinical trial to evaluate the effect ... including experimental antivirals. Sofosbuvir, the clinically approved anti-hepatitis C virus (HCV) drug, is ... COVID-19 is a devastating global pandemic around the world. While the majority of infected cases ...
| Abstract | COVID-19 is a devastating global pandemic around the world. While the majority of infected cases appear mild, in some cases individuals present respiratory complications with possible serious lung damage. There are no specific treatments for COVID-19 as yet, though a number are under evaluation, including experimental antivirals. Sofosbuvir, the clinically approved anti-hepatitis C virus (HCV) drug, is also capable of suppressing other families of positive-strand RNA viruses; Flaviviridae and Togaviridae. Coronaviruses are a family of positive-strand RNA viruses with conserved polymerase, so SARS-CoV-2 RdRp is very likely to be effectively inhibited by sofosbuvir. More importantly, sofosbuvir is safe and well tolerated at 400 mg daily in a 24 week therapeutic regimen. Sofosbuvir active metabolite, however, shows an extremely high intracellular stability So, it is hypothesized that SARS-CoV-2 infection could also be susceptible to sofosbuvir and we were convinced to design and run a clinical trial to evaluate the effect of sofosbuvir 400 mg (in combination with velpatasvir 100 mg, as add-on treatment, in addition to standard of care) on the COVID-19. However, we believe that this manuscript/correspondence should be made available to the international scientific community as soon as possible, with the help of this esteemed journal. |
|---|---|
| MeSH term(s) | Antiviral Agents/administration & dosage ; Betacoronavirus ; COVID-19 ; Carbamates/administration & dosage ; Clinical Trials as Topic ; Coronavirus Infections/drug therapy ; Drug Repositioning ; Heterocyclic Compounds, 4 or More Rings/administration & dosage ; Humans ; Iran ; Pandemics ; Patient Safety ; Pneumonia, Viral/drug therapy ; SARS-CoV-2 ; Sofosbuvir/administration & dosage |
| Chemical Substances | Antiviral Agents ; Carbamates ; Heterocyclic Compounds, 4 or More Rings ; velpatasvir (KCU0C7RS7Z) ; Sofosbuvir (WJ6CA3ZU8B) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-04-29 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 1156844-6 |
| ISSN | 1873-5487 ; 0188-4409 ; 0188-0128 |
| ISSN (online) | 1873-5487 |
| ISSN | 0188-4409 ; 0188-0128 |
| DOI | 10.1016/j.arcmed.2020.04.018 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 1001: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.